Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy

American Heart Journal

Volumn 165, Issue 5, 2013, Pages 704-709

  Urban, Philip ^a   Abizaid, Alex ^b   Chevalier, Bernard ^c   Greene, Samantha ^d   Meredith, Ian ^e   Morice, Marie Claude ^c   Pocock, Stuart ^f  

^a LA TOUR HOSPITAL   (Switzerland)

^b INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^c CERC   (France)

^d Biosensors International   (Switzerland)

^e MONASH MEDICAL CENTRE   (Australia)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; UMIROLIMUS;

ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; BLEEDING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ELUTING STENT; EQUIPMENT DESIGN; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; STENT THROMBOSIS; TREATMENT DURATION;

ABSORBABLE IMPLANTS; ASIA; CANADA; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; DRUG-ELUTING STENTS; EUROPE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INCIDENCE; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK FACTORS; SOUTH AMERICA; TIME FACTORS;

EID: 84876805919     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.01.008     Document Type: Article

References (34)

1. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes New Engl J Med 357 2007 2001 2015
2. Flavio Airoldi, Antonio Colombo, and Nuccia Morici Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment Circulation 116 2007 745 754
3. P.G. Steg, K. Huber, and F. Andreotti Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology Eur Heart J 32 2011 1854 1864
4. N. Ekerstad, E. Swahn, and M. Janzon Frailty is independently associated with short-term outcomes for elderly patients with non-ST-segment elevation myocardial infarction Circulation 124 2011 2397 2404
5. S.S. Jolly, S. Yusuf, and J. Cairns Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial Lancet 377 2011 1409 1420
6. D.T. Ko, L. Yun, and H.C. Wijeysundera Incidence, predictors, and prognostic implications of hospitalization for late bleeding after percutaneous coronary intervention for patients older than 65 years Circ Cardiovasc Interv 3 2010 140 147
7. M.L. Hansen, R. Sørensen, and M.T. Clausen Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation Arch Intern Med 170 2010 1433 1441
8. S. Subherwal, R.G. Bach, and A.Y. Chen Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score Circulation 119 2009 1873 1882
9. R. Mehran, S.J. Pocock, and E. Nikolsky A risk score to predict bleeding in patients with acute coronary syndromes J Am Coll Cardiol 55 2010 2556 2566
10. P. Urban, A. Abizaid, and A. Banning Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT (Multi-Center Post-Market Surveillance) registry J Am Coll Cardiol 57 2011 1445 1454
11. W. Wijns, P. Kolh, and N. Danchin Guidelines on myocardial revascularization. The Task Force on Myocardial revascularization of the European Society of Cardiology (ESC and the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J 31 2010 2501 2555
12. G.N. Levine, E.R. Bates, and J.C. Blankenship 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions Circulation 124 2011 e574 e651
13. A.J. Kirtane, A. Gupta, and S. Iyengar Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies Circulation 119 2009 3198 3206
14. S. Windecker, A. Remondino, and F. Eberli Sirolimus-eluting and Paclitaxel-eluting stents for coronary revascularization New Eng J Med 353 2005 653 662
15. S. Windecker, P.W. Serruys, and S. Wandel Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 2008 1163 1173
16. E. Kedhi, K.S. Joesoef, and E. McFadden Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209
17. P.W. Serruys, S. Silber, and S. Garg Comparison of zotarolimus-eluting and everolimus-eluting coronary stents N Eng J Med 363 2010 136 146
18. K. Rasmussen, M. Maeng, and A. Kaltoft Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial Lancet 375 2010 1090 1099
19. P. Wenaweser, J. Daemen, and M. Zwahlen Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study J Am Coll Cardiol 52 2008 1134 1140
20. S. Cook, E. Ladich, and G. Nakazawa Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis Circulation 120 2009 391 399
21. G.G. Stefanini, B. Kalesan, and P.W. Serruys Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4-year follow-up of a randomized non-inferiority trial Lancet 378 2011 1940 1948
22. S.J. Park, D.W. Park, and Y.H. Kim Duration of dual antiplatelet therapy after implantation of drug-eluting stents New Engl J Med 362 2010 1374 1382
23. M. Valgimigli, G. Campo, and M. Monti Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 2012 2015 2026
24. H.C. Gwon, J.Y. Hahn, and K.W. Park Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study Circulation 125 2012 Jan 24 505 513
25. B.K. Kim, M.K. Hong, and D.H. Shin A new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (REal Safety and Efficacy of 3 months dual antiplatelet Therapy following Endeavor Zotarolimus-eluting stent implantation) J Am Coll Cardiol 60 2012 1340 1348
26. N. Tada, R. Virmani, and G. Grant Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model Circ Cardiovasc Interv 3 2010 174 183
27. Grube E. BioFreedom First in Man 2 year outcomes - TCT San Francisco, November 7, 2011
28. C. Chan, Y.L. Lim, and T. Santoso Acute and long-term clinical and angiographic outcome after S-Stent implantation: S-Stent multicenter safety and efficacy trial Catheter Cardiovasc Interv 62 2004 439 444
29. L. Räber, H. Kelbæk, and M. Ostojic Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial JAMA 308 2012 777 787
30. K. Thygesen, J.S. Alpert, and A.S. Jaffe Third universal definition of myocardial infarction Eur Heart J 33 2012 2551 2567
31. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
32. R. Mehran, S.V. Rao, and D.L. Bhatt Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
33. G.W. Stone, S.G. Ellis, and D.A. Cox A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease New Eng J Med 350 2004 221 229
34. J. Pache, A. Kastrati, and J. Mehilli Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial J Am Coll Cardiol 41 2003 1283 1288